BETWEENGlobal Clinical Trials Agreement • January 21st, 2003 • Quest Diagnostics Inc • Services-medical laboratories • Delaware
CONFIDENTIAL Letter of Agreement between SmithKline Beecham Corporation And Quest Diagnostics IncorporatedGlobal Clinical Trials Agreement • February 22nd, 2008 • Quest Diagnostics Inc • Services-medical laboratories
This Letter of Agreement (“LOA”), effective as of January 1, 2008, is made between SmithKline Beecham Corporation d/b/a GlaxoSmithKline with a primary address at 2301 Renaissance Blvd, King of Prussia, PA 19406 USA, together with its affiliates (“GlaxoSmithKline” or “GSK”) and Quest Diagnostics Incorporated, with a primary address at 3 Giralda Farms, Madison, NJ 07940 together with its affiliates (“Quest Diagnostics”) together “the Parties”, to revise the relationship previously established in the Amended and Restated Global Clinical Trials Agreement dated December 19, 2002 (hereinafter “Previous Agreement”). “Affiliates” for purposes of this LOA shall include any corporation or non-corporate entity which controls, is controlled by, or is under common control with a Party to this LOA.
Exhibit 10.18 FIRST AMENDMENT TO GLOBAL CLINICAL TRIALS AGREEMENT This First Amendment to Global Clinical Trials Agreement (the "First Amendment") dated January 18, 2001 with an Effective Date of January 1, 2000 (the "Effective Date"), is made between...Global Clinical Trials Agreement • March 4th, 2002 • Quest Diagnostics Inc • Services-medical laboratories
